Andapsin (Sucralfate): Uses, Dosage & Side Effects
Mucosal Protective Agent — Forms a protective barrier over stomach and duodenal ulcers
Quick Facts About Andapsin
Key Takeaways About Andapsin
- Local protective action: Andapsin works by forming a physical barrier over ulcerated tissue rather than reducing stomach acid production. It is minimally absorbed into the body, which contributes to its favorable safety profile
- Take on an empty stomach: For optimal effectiveness, take Andapsin at least one hour before meals. Food can interfere with the medication's ability to bind to the ulcer site
- Avoid concurrent antacids: Do not take antacids at the same time as Andapsin. Antacids raise stomach pH and can prevent sucralfate from properly activating. Separate doses by at least 30 minutes
- Important drug interactions: Andapsin can reduce the absorption of many medications including warfarin, fluoroquinolone antibiotics, tetracyclines, and ketoconazole. Take other medications at least 2 hours before or after Andapsin
- Caution with kidney impairment: Patients with reduced kidney function should use Andapsin with care due to the risk of aluminum accumulation, which can lead to bone disease, encephalopathy, or anemia
What Is Andapsin and What Is It Used For?
Andapsin contains sucralfate, a mucosal protective agent that works locally in the gastrointestinal tract. In the acidic environment of the stomach, sucralfate forms a viscous, adhesive paste that binds selectively to ulcerated or eroded mucosal tissue, creating a protective barrier against hydrochloric acid, pepsin, and bile salts. This barrier persists for several hours, allowing ulcers to heal naturally.
Andapsin belongs to a unique class of gastrointestinal medications known as mucosal protective agents. Unlike proton pump inhibitors (PPIs) or H2 receptor antagonists that reduce acid secretion, sucralfate provides a physical shield over damaged tissue. This fundamentally different mechanism of action makes it a valuable therapeutic option, particularly for patients who cannot tolerate acid-suppressing medications or who need additional mucosal protection.
The active ingredient, sucralfate, is a complex of aluminum hydroxide and sulfated sucrose. When it reaches the acidic environment of the stomach (pH below 4), it undergoes a chemical transformation: the molecule cross-links and polymerizes, forming a thick, paste-like substance. This gel has a strong affinity for positively charged proteins that are exposed at ulcer sites, allowing it to bind preferentially to damaged tissue rather than healthy mucosa. Research has demonstrated that sucralfate's binding to ulcer craters is approximately six to eight times stronger than its binding to normal gastric epithelium.
Once bound, the sucralfate barrier serves multiple protective functions. It prevents hydrochloric acid from reaching the ulcer bed, blocks the proteolytic enzyme pepsin from further degrading damaged tissue, and shields against bile salts that may reflux from the duodenum into the stomach. Additionally, preclinical and clinical studies have suggested that sucralfate may stimulate local prostaglandin synthesis, enhance mucosal blood flow, and promote the production of epidermal growth factor—all of which contribute to the natural healing process.
A notable pharmacological advantage of sucralfate is its minimal systemic absorption. Less than 5% of an oral dose is absorbed into the bloodstream under normal conditions, with the remainder acting exclusively within the gastrointestinal lumen. This local action means that sucralfate produces very few systemic side effects, distinguishing it from many other gastrointestinal medications. The small amount of aluminum that is absorbed is normally excreted by the kidneys.
Common Indications
Andapsin is prescribed for several gastrointestinal conditions where mucosal protection and ulcer healing are needed:
- Duodenal ulcer treatment: Sucralfate is effective for healing active duodenal ulcers, with clinical studies demonstrating healing rates comparable to H2 receptor antagonists at 4–8 weeks. It is particularly useful in patients who prefer a non-acid-suppressing approach.
- Gastric ulcer treatment: Healing of active benign gastric ulcers, typically requiring a somewhat longer treatment course than duodenal ulcers. Endoscopic confirmation of healing is generally recommended.
- Prevention of recurrent duodenal ulcers: Maintenance therapy at reduced doses can help prevent ulcer recurrence in patients with a history of repeated duodenal ulceration.
- Stress ulcer prophylaxis: In critically ill patients (intensive care settings), sucralfate has been used to prevent stress-related mucosal damage and gastrointestinal bleeding. Some guidelines favor it over acid-suppressing agents in this context because it does not raise gastric pH, potentially reducing the risk of nosocomial pneumonia.
- NSAID-associated gastropathy: Protection of gastric mucosa in patients requiring long-term nonsteroidal anti-inflammatory drug (NSAID) therapy, although PPIs are generally preferred for this indication in current guidelines.
In the acidic stomach environment (pH < 4), sucralfate undergoes cross-linking and polymerization to form a viscous, adhesive gel. This gel binds to positively charged proteins exposed at ulcer sites through electrostatic interactions, creating a durable protective layer. The barrier is impermeable to hydrochloric acid, pepsin, and bile salts. It also stimulates local prostaglandin E2 synthesis and mucosal blood flow, promotes epithelial cell migration, and enhances secretion of bicarbonate and mucus—all contributing to accelerated healing. The protective layer typically persists for up to 6 hours after a single dose.
What Should You Know Before Taking Andapsin?
Before taking Andapsin, inform your doctor about any kidney problems, as sucralfate contains aluminum that may accumulate in patients with impaired renal function. Do not take Andapsin if you are allergic to sucralfate or any of its ingredients. Inform your healthcare provider about all other medications you are taking, as sucralfate can significantly affect the absorption of many drugs.
While Andapsin has an excellent safety profile due to its predominantly local action, there are important factors to consider before starting treatment. Understanding these precautions ensures safe and effective use of the medication and helps prevent potential complications.
Contraindications
You should not take Andapsin if:
- Allergy to sucralfate: If you have a known hypersensitivity to sucralfate or any other ingredient in Andapsin, you should not take this medication. Allergic reactions, while rare, can include itching, hives, swelling, and difficulty breathing.
- Allergy to excipients: The oral suspension formulation contains sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217), which may cause allergic reactions (possibly delayed) in sensitive individuals. Check the full ingredient list if you have known sensitivities to preservatives.
Warnings and Precautions
Speak with your healthcare provider before taking Andapsin if any of the following conditions apply to you:
Patients with impaired renal function should consult their doctor before starting Andapsin. Sucralfate contains aluminum, and while systemic absorption is normally minimal, patients with kidney disease cannot efficiently excrete even small amounts of absorbed aluminum. Over time, this can lead to aluminum accumulation, which may cause:
- Aluminum-related bone disease (osteomalacia): Softening of bones due to aluminum interference with calcium metabolism
- Encephalopathy: Neurological symptoms including confusion, speech difficulties, and seizures
- Anemia: Reduced red blood cell production due to aluminum toxicity
If you have chronic kidney disease or are on dialysis, your doctor should closely monitor aluminum levels during treatment.
Bezoar formation: There have been reports of bezoars (masses of undigested material accumulating in the stomach or intestines) in patients taking sucralfate. This risk is elevated in patients with gastrointestinal motility disorders—whether caused by surgery, medication, or underlying disease that reduces normal gut movement. If you have a history of gastroparesis, post-surgical ileus, or are taking medications that slow gastrointestinal motility (such as opioids or anticholinergics), inform your doctor before starting Andapsin.
Citrate-containing products: Andapsin should not be taken at the same time as citrate-containing products, including effervescent tablets and certain soft drinks. Citric acid can significantly increase the absorption of aluminum from sucralfate, raising the risk of elevated blood aluminum levels. Allow at least 2 hours between Andapsin and any citrate-containing food or drink. This precaution is particularly important for patients with impaired kidney function.
Pregnancy and Breastfeeding
No adverse effects on the fetus have been demonstrated with sucralfate use during pregnancy. Because sucralfate acts locally in the gastrointestinal tract and has minimal systemic absorption (less than 5% of the oral dose), the potential for fetal exposure is very low. This favorable safety profile makes sucralfate one of the preferred options for treating peptic ulcer disease during pregnancy when medication is deemed necessary.
Sucralfate does not pass into breast milk, making it compatible with breastfeeding. However, as with any medication during pregnancy or lactation, it is advisable to consult your healthcare provider before initiating treatment to weigh the benefits against any potential risks in your individual situation.
Driving and Operating Machinery
Andapsin has no known effect on the ability to drive or operate machinery. Since sucralfate acts locally in the gastrointestinal tract and is minimally absorbed, it does not produce central nervous system effects such as drowsiness, dizziness, or impaired concentration. You may safely drive and perform tasks requiring alertness while taking this medication.
Sodium Content
Andapsin oral suspension contains 4.4–8.8 mg of sodium per dose (5–10 ml). A maximum daily dose of 30 ml corresponds to approximately 1.3% of the WHO-recommended maximum daily intake of sodium for adults. This amount is considered clinically insignificant, but patients on strictly sodium-restricted diets should be informed.
How Does Andapsin Interact with Other Drugs?
Andapsin can reduce the absorption of many medications by binding to them in the gastrointestinal tract. The most clinically significant interactions involve warfarin, fluoroquinolone antibiotics, tetracyclines, ketoconazole, and theophylline. As a general rule, take other medications at least 2 hours before or 2 hours after Andapsin to minimize the risk of reduced absorption.
Drug interactions with Andapsin occur primarily through a physical mechanism: sucralfate can bind to other medications in the gastrointestinal tract, reducing their absorption and potentially decreasing their effectiveness. This is fundamentally different from the metabolic interactions seen with many other drugs. Because sucralfate forms a viscous gel in the stomach, any co-administered oral medication can become entrapped or bound, leading to reduced bioavailability.
Additionally, antacids should not be taken simultaneously with Andapsin. Sucralfate requires an acidic environment (pH below 4) to undergo the polymerization and cross-linking reactions necessary for its activation. Antacids raise the gastric pH, potentially preventing sucralfate from forming its protective gel. If antacid therapy is also needed, take the antacid at least 30 minutes before or after Andapsin.
Major Interactions
The following interactions are considered clinically significant and require careful timing of doses or additional monitoring:
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Warfarin | Sucralfate may reduce warfarin absorption, decreasing its anticoagulant effect | Monitor INR closely; take warfarin 2 hours before sucralfate |
| Ciprofloxacin | Sucralfate binds to fluoroquinolones via aluminum chelation, reducing absorption by up to 90% | Take ciprofloxacin 2 hours before or 2 hours after sucralfate |
| Norfloxacin / Ofloxacin | Same aluminum chelation mechanism as ciprofloxacin | Separate doses by at least 2 hours; antibiotic first |
| Tetracycline / Doxycycline | Aluminum in sucralfate chelates tetracyclines, dramatically reducing absorption | Take tetracycline 2 hours before or 2 hours after sucralfate |
| Ketoconazole | Reduced ketoconazole absorption due to binding and pH effects | Take ketoconazole 2 hours before or 2 hours after sucralfate |
| Phenytoin | Sucralfate may reduce phenytoin absorption | Monitor phenytoin levels; separate doses by 2 hours |
Other Notable Interactions
The following interactions require awareness and appropriate dose separation:
| Drug | Effect | Action Required |
|---|---|---|
| Theophylline | Reduced theophylline absorption | Separate doses by 2 hours; monitor theophylline levels |
| Digoxin | Potentially reduced digoxin absorption | Separate doses by 2 hours; monitor digoxin levels |
| Amitriptyline | Reduced amitriptyline absorption | Take amitriptyline 2 hours before sucralfate |
| Lymecycline / Oxytetracycline | Reduced antibiotic absorption via chelation | Separate doses by at least 2 hours |
| Antacids | Antacids raise gastric pH, preventing sucralfate activation | Take antacids 30 minutes before or after sucralfate |
| Levothyroxine | Reduced thyroid hormone absorption | Take levothyroxine at least 2 hours before sucralfate |
Because sucralfate can bind to a wide range of medications in the gastrointestinal tract, the safest approach is to take all other oral medications at least 2 hours before or 2 hours after your Andapsin dose. Always inform your doctor or pharmacist about all medications you are taking—including prescription drugs, over-the-counter products, vitamins, and herbal supplements—before starting Andapsin. If you are taking medications with a narrow therapeutic index (such as warfarin, phenytoin, digoxin, or theophylline), your doctor may need to monitor drug levels more closely during concurrent sucralfate therapy.
What Is the Correct Dosage of Andapsin?
The recommended adult dose of Andapsin is 2–4 grams daily, divided into 2–4 doses. The oral suspension should be shaken well before each use and taken on an empty stomach, at least one hour before meals. Your doctor will determine the appropriate dose and duration based on your specific condition.
Andapsin dosing is determined by your healthcare provider based on the type and severity of your condition. The following guidelines represent standard dosing recommendations according to international prescribing information. Adherence to the prescribed dosing schedule is essential for optimal ulcer healing, as regular dosing ensures that a protective barrier is maintained over the ulcer site throughout the day.
Adults
| Condition | Dose | Duration |
|---|---|---|
| Active duodenal ulcer | 1 g four times daily (before meals and at bedtime) or 2 g twice daily | 4–8 weeks |
| Active gastric ulcer | 1 g four times daily (before meals and at bedtime) | 4–8 weeks (up to 12 weeks) |
| Maintenance / prevention of duodenal ulcer recurrence | 1 g twice daily | Up to 12 months under medical review |
| Stress ulcer prophylaxis (hospital setting) | 1 g four to six times daily (via nasogastric tube or oral) | Duration of ICU stay or as directed |
For the oral suspension (200 mg/ml), 1 gram corresponds to 5 ml. A typical active treatment dose of 4 grams per day would therefore require 20 ml of suspension daily, divided into four 5 ml doses. Your doctor may prescribe a different regimen based on your individual needs.
Children and Adolescents
Pediatric Use
Andapsin is not recommended for children under 14 years of age due to insufficient clinical data in this population. There are limited studies evaluating the safety and efficacy of sucralfate in pediatric patients. If a physician considers sucralfate necessary for an adolescent aged 14 and above, the adult dosing regimen is generally applied, though under close medical supervision.
Always consult a pediatric gastroenterologist before using sucralfate in patients under 18 years of age.
Elderly Patients
No specific dose adjustment is generally required for elderly patients with normal kidney function. However, because age-related decline in renal function is common and may not always be reflected in standard blood tests, healthcare providers should assess kidney function before starting treatment in elderly patients. If renal impairment is present, more cautious use and monitoring for aluminum accumulation may be warranted.
Elderly patients may also be more susceptible to constipation (the most common side effect of sucralfate) and may benefit from increased fluid intake and dietary fiber during treatment. If constipation becomes problematic, consult your doctor rather than self-treating with aluminum-containing antacids, which could compound the issue.
How to Take Andapsin
For optimal effectiveness, follow these instructions carefully:
- Empty stomach: Take Andapsin at least one hour before meals. An empty stomach ensures that sucralfate can reach and bind to the ulcer site without interference from food particles. The acidic gastric environment present between meals is also optimal for sucralfate activation.
- Shake well: Before each dose of the oral suspension, shake the bottle vigorously to ensure uniform distribution of the active ingredient. Sucralfate tends to settle, and inadequate shaking may result in inconsistent dosing.
- Consistency: Take your doses at regular intervals throughout the day for the best ulcer protection. A common schedule is 30–60 minutes before breakfast, lunch, dinner, and at bedtime.
- Full course: Complete the prescribed treatment course even if your symptoms improve before the end of treatment. Ulcers may appear healed symptomatically before complete mucosal repair has occurred.
- Avoid citrates: Do not take Andapsin within 2 hours of consuming citrate-containing food or drinks (including some effervescent tablets and carbonated beverages), as citric acid can increase aluminum absorption.
Missed Dose
If you forget to take a dose, take it as soon as you remember, provided you are still at least one hour before your next meal. If it is nearly time for your next scheduled dose, skip the missed dose entirely and continue with your regular dosing schedule. Do not take a double dose to compensate for a missed one. Missing occasional doses will reduce the overall protection of the ulcer site but is unlikely to cause harm.
Overdose
If you take more Andapsin than prescribed, or if a child accidentally ingests the medication, contact your local poison control center or seek medical attention. Because sucralfate is minimally absorbed from the gastrointestinal tract, acute overdose is unlikely to cause serious systemic toxicity. Symptoms of overdose are generally limited to gastrointestinal discomfort, including nausea, vomiting, and abdominal pain. There is no specific antidote; treatment is supportive and symptomatic. In cases of chronic excessive use, particularly in patients with renal impairment, monitoring for aluminum accumulation may be appropriate.
What Are the Side Effects of Andapsin?
Andapsin is generally well tolerated because it acts locally and is minimally absorbed. The most common side effect is constipation, occurring in up to 1 in 10 patients. Dry mouth and nausea are uncommon. Serious side effects are rare but include allergic reactions and, in patients with kidney impairment, aluminum accumulation leading to bone disease, encephalopathy, or anemia.
Because sucralfate acts locally in the gastrointestinal tract with minimal systemic absorption, it has a favorable side effect profile compared to many other gastrointestinal medications. Most side effects are mild and related to the local presence of the medication in the gut. However, as with all medications, some patients may experience adverse reactions. The following information is organized by frequency of occurrence according to standard medical classification.
Common Side Effects
- Constipation: The most frequently reported side effect, occurring because the aluminum component of sucralfate has a constipating effect. This can usually be managed with increased fluid intake and dietary fiber. If constipation is severe or persistent, consult your doctor.
Uncommon Side Effects
- Dry mouth (xerostomia): Some patients experience a feeling of dryness in the mouth, likely related to the binding properties of sucralfate in the oral cavity
- Nausea: Mild nausea that typically resolves with continued use or can be minimized by taking the medication as directed on an empty stomach
Rare Side Effects
- Skin rash: Mild cutaneous reactions including redness or irritation
- Urticaria (hives): Raised, itchy welts on the skin that may indicate an allergic response
- Bezoar formation: Accumulation of undigested material in the stomach or intestines, primarily in patients with impaired gastrointestinal motility
Frequency Not Known
- Allergic reactions: Symptoms may include itching, hives (urticaria), edema (swelling), and difficulty breathing. Seek immediate medical attention if you experience these symptoms
Patients with Kidney Impairment
In patients with impaired renal function, even the small amounts of aluminum absorbed from sucralfate may accumulate in the body because the kidneys cannot excrete it efficiently. Over time, this aluminum accumulation can lead to several serious conditions:
- Aluminum-related bone disease (osteomalacia): Aluminum disrupts normal bone mineralization by interfering with calcium and phosphate metabolism. This can lead to bone pain, fractures, and skeletal deformities. The condition may develop gradually over months of treatment.
- Dialysis encephalopathy: In patients on dialysis, aluminum accumulation in the brain can cause progressive neurological deterioration, including speech difficulties, memory loss, tremors, myoclonus, and seizures.
- Microcytic anemia: Aluminum can inhibit hemoglobin synthesis and iron incorporation into red blood cells, leading to a form of anemia that does not respond to iron supplementation.
For this reason, patients with chronic kidney disease (particularly stages 3–5 or those on dialysis) should only use sucralfate under close medical supervision with regular monitoring of serum aluminum levels.
If you experience any side effects, including those not listed above, report them to your healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting helps ensure the ongoing safety monitoring of medications.
How Should You Store Andapsin?
Store Andapsin oral suspension at or below 25°C (77°F). Keep the medication out of sight and reach of children. Do not use after the expiration date printed on the packaging. Shake the bottle well before each use.
Proper storage of Andapsin ensures the medication retains its efficacy throughout the treatment period. The oral suspension is a physical suspension that can separate over time, so proper handling is essential.
- Temperature: Store the oral suspension at or below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
- Children: Keep out of sight and reach of children. Sucralfate suspension may have a sweet taste (due to saccharin and flavoring agents) that could attract children.
- Expiration: Do not use Andapsin after the expiration date printed on the carton and bottle. The expiration date refers to the last day of the indicated month.
- Disposal: Do not dispose of medications via household waste or down the drain. Return unused medications to your pharmacy for proper disposal to protect the environment.
- Before each use: Shake the bottle well before measuring your dose to ensure uniform distribution of the active ingredient in the suspension.
What Does Andapsin Contain?
Andapsin oral suspension contains the active substance sucralfate (200 mg per ml). The suspension also contains inactive ingredients including saccharin sodium (sweetener), sodium dihydrogen phosphate dihydrate, glycerol, preservatives (E219 and E217), xanthan gum, flavoring agents, and purified water.
Understanding the full composition of your medication is important for identifying potential allergens or substances you may be sensitive to. Below is the complete list of ingredients in the Andapsin oral suspension formulation.
Active Ingredient
The active substance is sucralfate (aluminum sucrose sulfate). Each milliliter of the oral suspension contains 200 mg of sucralfate. Sucralfate is a complex of aluminum hydroxide and sulfated sucrose that forms a protective gel in the acidic environment of the stomach.
Inactive Ingredients (Excipients)
The oral suspension contains the following inactive ingredients:
- Saccharin sodium: A non-caloric sweetener used to improve the taste of the suspension
- Sodium dihydrogen phosphate dihydrate: A buffering agent that helps maintain the stability of the formulation
- Glycerol: A humectant and viscosity modifier that contributes to the smooth texture of the suspension
- Sodium methyl parahydroxybenzoate (E219): A preservative. May cause allergic reactions (possibly delayed) in sensitive individuals
- Sodium propyl parahydroxybenzoate (E217): A preservative. May cause allergic reactions (possibly delayed) in sensitive individuals
- Xanthan gum: A thickening and stabilizing agent that helps keep the sucralfate uniformly suspended
- Flavoring agents: Caramel and anise flavors to improve palatability
- Purified water: The vehicle for the suspension
The Andapsin oral suspension is a white liquid with a caramel flavor. It is supplied in 200 ml plastic bottles or in unit-dose sachets (120 × 5 ml).
This medication contains 4.4–8.8 mg sodium per dose (5–10 ml). A daily dose of 30 ml corresponds to approximately 1.3% of the WHO-recommended maximum daily intake of sodium for adults (2 g/day). This amount is considered essentially sodium-free for most patients.
Manufacturer
Andapsin is manufactured by Orion Corporation (Orion Pharma), headquartered in Espoo, Finland. The oral suspension is produced at Orion Pharma facilities in Kuopio and Salo, Finland. These manufacturing sites operate under European Good Manufacturing Practice (GMP) standards.
Frequently Asked Questions About Andapsin
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Sucralfate — Summary of Product Characteristics." EMA Official European regulatory documentation for sucralfate-containing medications.
- U.S. Food and Drug Administration (FDA). "Sucralfate — Prescribing Information (Carafate)." FDA FDA-approved labeling and safety information for sucralfate.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines — 23rd list." WHO Essential Medicines International reference for essential gastrointestinal medications.
- British National Formulary (BNF). "Sucralfate: Indications, dose, contraindications, side effects, interactions." BNF / NICE Comprehensive UK drug monograph including dosing and interaction data.
- Marks IN, et al. (1980). "Ulcer healing and relapse rates after initial treatment with cimetidine or sucralfate." Journal of Clinical Gastroenterology. 2(Suppl 2):163–170. Early landmark study comparing sucralfate efficacy with H2 blockers for duodenal ulcer healing.
- Tryba M (1991). "Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate." Critical Care Medicine. 19(7):942–949. doi:10.1097/00003246-199107000-00019 Meta-analysis demonstrating lower pneumonia rates with sucralfate compared to pH-raising agents in ICU patients.
- Lanza FL (1987). "Sucralfate: An update." Hospital Practice. 22(8):191–206. Comprehensive review of sucralfate pharmacology, mechanism of action, and clinical applications.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in gastroenterology, pharmacology, and clinical medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Gastroenterology Specialists
Licensed physicians specializing in gastroenterology and hepatology, with documented experience in peptic ulcer disease and mucosal protective therapies.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing.
Researchers
Academic researchers with published peer-reviewed articles on gastrointestinal pharmacotherapy and mucosal protective agents.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in gastroenterology, pharmacology, internal medicine, and clinical research.